Pay in 4 interest-free payments of $5.12 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
The recently published randomised controlled Study of Tirzepatide Compared with Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CVOT) demonstrated that tirzepatide (up to 15 mg) was non-inferior to dulaglutide (1.5 mg) in reducing major adverse cardiovascular events (death from cardiovascular causes, myocardial infarction or stroke) in patients with T2DM and atherosclerotic CVD
Any GLP-1 stimulation is a secondary, incidental effect rather than a primary therapeutic mechanism
Clinicians must tailor titration schedules carefully, often utilizing digital adherence platforms and patient coaching to manage these hurdles effectively
Thyroid conditions Patients taking levothyroxine for hypothyroidism frequently use GLP-1 therapy concurrently
& Hanna, M
US$ 28.75
US$ 29.81
US$ 26.23
US$ 22.10
